Atsushi Naganuma

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7498172/publications.pdf

Version: 2024-02-01

	932766	996533
260	10	15
citations	h-index	g-index
7.0		001
19	19	321
docs citations	times ranked	citing authors
	citations 19	260 10 citations h-index 19 19

#	Article	IF	CITATIONS
1	Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluatorâ€blinded, activeâ€controlled trial and a phase III, multicenter, open trial. Hepatology Research, 2018, 48, 411-423.	1.8	36
2	Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals, 2021, 14, 36.	1.7	30
3	Analyses of objective response rate, progressionâ€free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. Hepatology Research, 2020, 50, 382-395.	1.8	28
4	Effect of 48â€week pemafibrate on nonâ€alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the <scp>FibroScanâ€</scp> aspartate aminotransferase score. JGH Open, 2021, 5, 1183-1189.	0.7	21
5	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Medicine, $2022,11,3796$ - 3808 .	1.3	21
6	The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study. Oncology, 2021, 99, 203-214.	0.9	18
7	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Hepatology Research, 2022, 52, 462-470.	1.8	18
8	Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. Cancers, 2020, 12, 2906.	1.7	17
9	Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015. Hepatology Research, 2017, 47, 435-445.	1.8	16
10	Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin. Hepatology Research, 2018, 48, E347-E353.	1.8	10
11	Role of deleterious single nucleotide variants in the coding regions of TNFAIP3 for Japanese autoimmune hepatitis with cirrhosis. Scientific Reports, 2019, 9, 7925.	1.6	10
12	Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study. Oncology, 2021, 99, 641-651.	0.9	9
13	Efficacy of Zinc Acetate Treatment for Patients with Decompensated Liver Cirrhosis Complicated by Hypozincemia. Biological Trace Element Research, 2022, 200, 497-504.	1.9	6
14	The prognosis of elderly patients with hepatocellular carcinoma: A multiâ€eenter 19â€year experience in Japan. Cancer Medicine, 2023, 12, 345-357.	1.3	5
15	Prediction of oral intake recovery for inpatients with aspiration pneumonia by videoendoscopic evaluation using the Hyodoâ€Komagane score in Japan. Journal of Oral Rehabilitation, 2021, 48, 55-60.	1.3	4
16	Calf circumference and stroke are independent predictors for an improvement in the food intake level scale in the Japanese sarcopenic dysphagia database. European Geriatric Medicine, 0, , .	1.2	4
17	Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. Oncology, 2022, 100, 65-73.	0.9	3
18	Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study. Oncology, 2022, 100, 449-459.	0.9	3

#	Article	IF	CITATIONS
19	Usefulness of Percutaneous Transesophageal Gastro-Tubing in Patients Receiving Chemoradiotherapy for Advanced Esophageal Cancer: A Case Report. Case Reports in Oncology, 2020, 12, 901-908.	0.3	1